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hould We Consider
ldosterone as the
rimary Screening Target for
reventing Cardiovascular Events?*
ary S. Francis, MD, FACC,
. H. Wilson Tang, MD
leveland, Ohio
here has been a growing literature on the genomic and
on-genomic effects of aldosterone contributing to hyper-
ension and cardiovascular diseases during the past decades
1). However, it was not until the recent publication of the
andomized Aldactone Evaluation Study (RALES) (2) and
he Eplerenone Post-Acute Myocardial Infarction Heart
ailure Efficacy and Survival Study (EPHESUS) (3) that
nterest grew in the pharmacologic blockade of aldosterone
eceptors for cardiovascular protection. In animal studies,
xcessive aldosterone has been associated with collagen
eposition, myocardial fibrosis, and myocardial remodeling
4). Blocking the synthesis or function of aldosterone also
as been demonstrated to improve diastolic dysfunction in
ypertensive patients with diastolic heart failure (5) and
mprove endothelial function in patients with asymptomatic
eft ventricular dysfunction or mild heart failure (6). Theo-
etically, aldosterone receptor antagonists are likely to be
eneficial across a broad spectrum of cardiovascular diseases.
owever, to date, the use of spironolactone has been mostly
estricted to patients with advanced heart failure (New York
eart Association functional class III or IV as in the
ALES trial), severe ascites, or hyperaldosteronism in the
bsence of renal insufficiency. The EPHESUS study added
atients with heart failure due to recent myocardial infarc-
ion to the mix, using the more selective aldosterone
eceptor blocker, eplerenone (3).
See page 1243
The association between excessive aldosterone and car-
iovascular morbidity in patients with hypertension was
escribed many years ago (7). The careful screening of
ldosterone-renin ratios has led to a 10-fold increase in the
etection rate of primary aldosteronism (8). The report of
illiez et al. (9) in this issue of the Journal re-examines this
elationship in the contemporary era. Using a matched
ase-control strategy in a relatively large patient population
*Editorials published in the Journal of American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Cardiovascular Medicine, Cleveland Clinic Foundation,m
leveland, Ohio. Dr. Francis is a consultant for Novartis Pharmaceuticals and has
eceived a research grant from Pfizer Pharmaceuticals to study eplerenone.rom a hypertension clinic, the authors found significantly
ore strokes, non-fatal myocardial infarction, and atrial
brillation in hypertensive patients with primary hyperaldo-
teronism (whether it was due to aldosterone-producing
denoma or bilateral adrenal hyperplasia) than in a group of
ypertensive patients without hyperaldosteronism who were
atched for age, gender, and blood pressure. These findings
dd to the growing literature that excessive aldosteronism
detected in as many as 10% of patients with “essential
ypertension” by careful hormonal evaluation) (10) may
ontribute to cardiovascular morbidity independent of ele-
ated blood pressures.
The case-control matching strategy is easily understood,
nd the authors have carefully matched known confounders
hat may influence the comparison. However, this matching
trategy requires early decisions about which variables are
onfounders and which are predictors. There are risks of
vermatching (i.e., matching on factors that are not neces-
arily confounders) as well as undermatching (i.e., unable to
atch confounding factors that are unknown or not docu-
ented, such as genetic predispositions and environmental
actors). Furthermore, if the matching variable (such as
ingle-time blood pressure measurement) is not fixed but
ould be modified by the predictor of interest (in this case,
ldosterone), then the predictor itself could become a
otential confounder and the interpretation may become
ifficult. Because serum aldosterone levels in the physiologic
ange can influence blood pressure when the levels are in the
ighest quartile (11), it is conceivable that serum aldoste-
one also might act as a confounder. In addition, because
nly the prevalences of past cardiovascular events were
ompared between the groups, a causal relationship between
xcessive aldosterone and incident cardiovascular events
ould not be established. Despite all the caveats, the report
y Milliez et al. (9) is provocative, and these results point to
otential benefits of aggressive screening for and prevention
f hyperaldosteronism in patients at risk of developing
ardiovascular diseases.
How should we proceed? The findings of Milliez et al. (9)
ay not necessary be novel, but if confirmed, might lead to
more widespread use of spironolactone or eplerenone for
atients with hypertension—a concept that has continued to
volve (12) and can be extrapolated from the benefits of
rescribing angiotensin-converting enzyme inhibitors for
t-risk patients (13,14). The logical next step is to conduct
“proof-of-concept” mortality trial using aldosterone recep-
or antagonists as add-on therapy for primary prevention in
atients with hyperaldosteronism. However, from the
ALES and EPHESUS trials, it is clear that the potential
enefits of aldosterone receptor blockade have to be bal-
nced against the costs and the potential risks associated
ith the use of aldosterone-blocking drugs, particularly in
lderly patients who are prone to hyperkalemia and renal
nsufficiency beyond the clinical trial setting (15). Further-
ore, the impact of aldosterone receptor antagonists used in
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Editorial Comment April 19, 2005:1249–50he setting of widespread use of angiotensin-converting
nzyme inhibitors or angiotensin receptor-blocking drugs
emains to be carefully evaluated. Perhaps the larger ques-
ion would be thus: is there ever going to be a change in the
aradigm for cardiovascular prevention, whereby targeted
outine screening (as in this case, careful identification of
atients with hyperaldosteronism) allows tailoring of ther-
py? Here lies the greatest challenge of our time—we will
nevitably need a concerted effort to develop innovative ways
eyond polypharmacy and randomized controlled trials to
ranslate clinical evidence into effective medical practices.
eprint requests and correspondence: Dr. Gary S. Francis,
epartment of Cardiovascular Medicine, Cleveland Clinic Foun-
ation, 9500 Euclid Avenue, Desk F25, Cleveland, Ohio 44195.
-mail: francig@ccf.org.
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